Thomas Edwards Wagner
Affiliations: | Ohio University, Athens, OH, United States |
Website:
https://www.ohio.edu/distinguishedprofessor/professors.cfmGoogle:
"Thomas E. Wagner" OR "Thomas Edwards Wagner"Bio:
http://www.perseuspci.com/us/
https://media.library.ohio.edu/digital/collection/archives/id/43468/
DOI: 10.1021/ja00961a049
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Robert Lewis Letsinger | grad student | 1966 | Northwestern | |
| (A study of the reaction of a polynucleotide derivative with cationic polybases.) | ||||
Children
Sign in to add trainee| Xiaozhuo Chen | grad student | 1988 | Ohio University |
| Yanzhang Wei | grad student | 1996 | Ohio University (Microtree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chick RC, Faries MB, Hale DF, et al. (2020) Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Journal of Clinical Oncology. 38: 63-63 |
| Chick RC, Hickerson AT, Clifton GT, et al. (2020) Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma Cancer Research. 80: 6536-6536 |
| Hickerson A, Clifton GT, Brown TA, et al. (2019) Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma. Journal of Clinical Oncology. 37 |
| Hickerson AT, Clifton GT, Brown TA, et al. (2019) Abstract CT208: Prior vaccination with the autologous Tumor Lysate Particle Loaded Dendritic Cell (TLPLDC) Vaccine may impact clinical outcomes in melanoma patients treated with systemic therapies and re-vaccination Cancer Research. 79 |
| Herbert GS, Vreeland TJ, Clifton GT, et al. (2018) Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Vaccine |
| Hardin MO, Vreeland TJ, Clifton GT, et al. (2018) Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. Immunotherapy. 10: 373-382 |
| Brown TA, Myers JW, Vreeland TJ, et al. (2018) Abstract CT150: Initial analysis of open-label administration of autologous tumor lysate (TL) + dendritic cells (DC) vaccine (TLPLDC) in melanoma patients who recurred during a phase IIb adjuvant vaccine trial Cancer Research. 78 |
| Peace KM, Vreeland TJ, Hale DF, et al. (2017) A novel cancer vaccine platform utilizing autologous tumor lysate loaded into capped yeast cell wall particles. Journal of Clinical Oncology. 35: 169-169 |
| Peace KM, Vreeland TJ, Clifton GT, et al. (2017) Abstract CT036: Early trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in ovarian cancer patients Cancer Research. 77 |
| Greene JM, Schneble EJ, Jackson DO, et al. (2016) A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunology, Immunotherapy : Cii |